Sanochemia Pharmazeutika AG
http://www.sanochemia.at/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sanochemia Pharmazeutika AG
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
FDA’s Dry January: Little Novel Application Activity, But That Doesn’t Mean No Fun
US FDA’s drugs center posted one of its lowest monthly approval counts of original applications in January, but new indications filled the gap, including new claims for Merck’s Keytruda, Takeda immunoglobulins, and Sanofi/Regeneron’s Dupixent.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Alvetra et al Werfft GmbH
- SANOCHEMIA Diagnostics Deutschland GmbH
- SANOCHEMIA Diagnostics International Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice